Aaron Kantoff

Mr. Aaron Kantoff is an independent member of the Board of Directors of Ceptur Therapeutics. He is a Venture Partner on the Medicxi investment team as well as a member of the Board of Directors of Centessa (NASDAQ: CNTA) and RayzeBio. Prior to Medicxi, Mr. Kantoff was a Partner at Apple Tree Partners (ATP; 2011-2019), where he was a key member of the life sciences investment team. While at ATP, he played a leading role in assembling several portfolio companies and served on the boards of Akero Therapeutics (NASDAQ: AKRO), Corvidia Therapeutics (acquired by Novo Nordisk), Marengo Therapeutics (fka Elstar Therapeutics), Limelight Bio, Stoke Therapeutics (NASDAQ: STOK) and Syntimmune (acquired by Alexion); he also led many of ATP’s crossover and public biotech investments. Prior to ATP, Mr. Kantoff held various roles in private equity and investment banking. He earned his B.S. in finance and international business from the Leonard N. Stern School of Business at New York University.